- Home
- GDOT vs ARVN Comparison
GDOT vs ARVN Comparison
Compare GDOT & ARVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GDOT | ARVN |
|---|---|---|
| Founded | 1999 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 693.8M | 781.0M |
| IPO Year | 2010 | 2018 |
Fundamental Metrics
Financial Performance| Metric | GDOT | ARVN |
|---|---|---|
| Price | $12.09 | $12.24 |
| Analyst Decision | Sell | Buy |
| Analyst Count | 2 | 23 |
| Target Price | $11.00 | ★ $18.14 |
| AVG Volume (30 Days) | 659.3K | ★ 792.5K |
| Earning Date | 02-26-2026 | 02-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,007,128,000.00 | $312,300,000.00 |
| Revenue This Year | $22.56 | $11.17 |
| Revenue Next Year | $11.63 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 23.16 | ★ 93.86 |
| 52 Week Low | $6.13 | $5.90 |
| 52 Week High | $15.41 | $20.38 |
Technical Indicators
Market Signals| Indicator | GDOT | ARVN |
|---|---|---|
| Relative Strength Index (RSI) | 35.24 | 53.70 |
| Support Level | $12.19 | $11.88 |
| Resistance Level | $12.59 | $12.79 |
| Average True Range (ATR) | 0.25 | 0.53 |
| MACD | -0.11 | 0.01 |
| Stochastic Oscillator | 3.00 | 68.02 |
Price Performance
Historical ComparisonAbout GDOT Green Dot Corporation $0.001 par value
Green Dot Corp is a financial technology company that provides financial services for consumers in the United States without good banking options. It has three segments Consumer Services, Business to Business Services(B2B), and Money Movement Services. The company generates maximum revenue from B2B segment. Its B2B Services segment consists of revenues and expenses derived from (i) its partnerships with prominent consumer and technology companies that make banking products and services available to their consumers, partners and workforce through integration with its banking platform (the "Banking-as-a-Service", or "BaaS channel"), and (ii) a comprehensive payroll platform that it offers to corporate enterprises (the "Employer channel") to facilitate payments for today's workforce.
About ARVN Arvinas Inc.
Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins.. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766.